 HEIDELBERG, Germany, Oct. 01, 2021 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer SITC, which will be held on November 10-14, 2021. 